Last reviewed · How we verify
hepatitis A inactivated virus vaccine — Competitive Intelligence Brief
phase 3
inactivated virus vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
hepatitis A inactivated virus vaccine (hepatitis A inactivated virus vaccine) — GlaxoSmithKline. This vaccine works by exposing the body to a small, harmless piece of the hepatitis A virus, prompting the immune system to produce antibodies that can fight the virus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| hepatitis A inactivated virus vaccine TARGET | hepatitis A inactivated virus vaccine | GlaxoSmithKline | phase 3 | inactivated virus vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (inactivated virus vaccine class)
- GlaxoSmithKline · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- hepatitis A inactivated virus vaccine CI watch — RSS
- hepatitis A inactivated virus vaccine CI watch — Atom
- hepatitis A inactivated virus vaccine CI watch — JSON
- hepatitis A inactivated virus vaccine alone — RSS
- Whole inactivated virus vaccine class — RSS
Cite this brief
Drug Landscape (2026). hepatitis A inactivated virus vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/hepatitis-a-inactivated-virus-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab